<?xml version="1.0" encoding="UTF-8"?>
<p>In one controlled open-label study (
 <italic>n</italic> = 24), patients were given either baricitinib 4 mg/day plus lopinavir–ritonavir or antiretroviral plus hydroxychloroquine (control group) for 2 weeks. Significant improvement of symptoms and laboratory results, no intensive care unit transfer (
 <italic>versus</italic> 33% transfer in control cases), and 58% discharge from wards (
 <italic>versus</italic> 8% in control) was shown among the baricitinib-treated individuals.
 <sup>
  <xref rid="bibr14-1759720X20947296" ref-type="bibr">14</xref>
 </sup>
</p>
